Intuitive Surgical Inc. ($ISRG) Stock Forecast: Up 5.3% Today

What is Intuitive Surgical Inc.?

Intuitive Surgical is a leading company in the healthcare sector, known for its innovative technologies in robotic-assisted minimally invasive surgery. The stock has recently faced a bearish trend, dropping 11% in the past month.

Why is Intuitive Surgical Inc. going up?

ISRG stock is up 5.3% on Jun 4, 2026 14:07

• Despite a recent 11% decline in ISRG shares, today's bullish movement could be attributed to several factors:
• The positive sentiment highlighting Intuitive Surgical as a strong contender in the healthcare sector may have attracted investors.
• The proposed sale of common stock could have been perceived as a routine financial decision rather than a cause for concern.
• Market participants may be viewing the recent pullback in ISRG shares as a buying opportunity, especially with the company's strong fundamentals and a Zacks Rank #2 (Buy) rating.
• The broader market concerns about ISRG's recent decline may have subsided, leading to renewed confidence in the stock's potential for growth.

ISRG Price Chart

ISRG Technical Analysis

ISRG News

Jim Cramer on Danaher: “At These Prices, It’s Clearly Overvalued”

Jim Cramer has stated that Danaher Corporation (NYSE: DHR) is currently overvalued, trading at 21 times earnings with only 4-6% organic growth. He contrasted this with Thermo Fisher, which trades at under 20 times earnings and has a 1% organic growth rate. Cramer noted Danaher's stock has been "pulverized" after a series of disappointing quarters, with the stock down 27% year-to-date, alongside other medical and diagnostic companies experiencing significant declines.

https://finance.yahoo.com/markets/stocks/articles/jim-cramer-danaher-prices-clearly-105830165.html

Sound Shore Management Inc. CT Has $76.50 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Sound Shore Management Inc. CT reduced its stake in Zimmer Biomet Holdings, Inc. by 5.1% in the fourth quarter, yet still held 850,757 shares valued at $76.5 million. Zimmer Biomet reported strong quarterly earnings, surpassing revenue and EPS estimates, and announced a quarterly dividend. The stock currently holds an average "Hold" rating from analysts with a target price of $102.70.

https://www.marketbeat.com/instant-alerts/filing-sound-shore-management-inc-ct-has-7650-million-stock-position-in-zimmer-biomet-holdings-inc-zbh-2026-06-04/

Intuitive Surgical: A Strong Contender in the Healthcare Sector

This article from The Motley Fool discusses Intuitive Surgical (NASDAQ: ISRG), highlighting it as a strong contender in the healthcare sector. It encourages potential investors to explore insights from expert analysts regarding market trends and investment opportunities. The report also mentions that while Intuitive Surgical is a recommended stock, it was not among the top 10 identified by The Motley Fool Stock Advisor analyst team, which has a track record of identifying high-growth stocks.

https://www.theglobeandmail.com/investing/markets/stocks/NFLX-Q/pressreleases/2293079/intuitive-surgical-a-strong-contender-in-the-healthcare-sector/

[144] INTUITIVE SURGICAL INC SEC Filing

This article reports on an SEC Form 144 filing by INTUITIVE SURGICAL INC (ISRG) dated June 3, 2026. The filing details a proposed sale of 12,472 shares of common stock with an aggregate market value of $5,017,485.60, acquired through the exercise of stock options, and indicates the sale will be conducted through Morgan Stanley Smith Barney LLC on NASDAQ. The document also includes standard SEC disclosures, filer and issuer information, and certifies that the filer knows no material adverse information about the issuer that has not been publicly disclosed.

https://www.stocktitan.net/sec-filings/ISRG/144-intuitive-surgical-inc-sec-filing-e9b61bd727e0.html

ISRG Falls 11% in a Month: Is a Reversal on the Cards for the Stock?

Intuitive Surgical (ISRG) shares have dropped 11% in the past month despite strong Q1 2026 results, driven by broader market concerns rather than operational performance. The article explores catalysts for a potential recovery, including the da Vinci 5 platform, a robust digital ecosystem, international expansion, and emerging growth platforms. Despite premium valuation and competition, the pullback is seen as a buying opportunity given strong fundamentals and a Zacks Rank #2 (Buy) rating.

https://www.tradingview.com/news/zacks:a52982d7c094b:0-isrg-falls-11-in-a-month-is-a-reversal-on-the-cards-for-the-stock/

Trending Today

Aave ($AAVE) Crypto Forecast: Down 5.2% Today

Intuitive Surgical Inc. Price History

02.05.2026 - ISRG Stock was down 5.6%

• Price target adjustment and Sell rating from Deutsche Bank likely contributed to the bearish movement, indicating a pessimistic outlook on ISRG's performance.
• The appointment of Taylor Patton as Chief Commercial and Marketing Officer raised questions about the company's strategic direction, potentially causing uncertainty among investors.
• Despite the positive trading session for the broader market, ISRG underperforming its competitors and experiencing a decline in share price suggests specific company-related factors at play.
• The intensifying competition in the robotic surgery market and the need for global expansion may have added pressure on ISRG's stock performance, leading to the bearish movement.

22.03.2026 - ISRG Stock was up 6.9%

• ISRG stock saw a drop despite surpassing first-quarter predictions and increasing full-year guidance, potentially due to the guidance raise falling short of market expectations, indicating a likely slowdown ahead.
• Although showing a robust performance in Q1, marked by a 23% surge in sales and notable growth in da Vinci and Ion procedures, ISRG's careful guidance overshadowed its achievements, contributing to the bearish market trend.
• Investors seemed to react to the disparity between the impressive earnings report and the company's conservative forecast, leading to a stock decline despite positive operational outcomes.
• The market sentiment surrounding ISRG seems to reflect a balance between present performance and future growth possibilities, resulting in a varied response from investors.

22.03.2026 - ISRG Stock was up 5.7%

• Despite surpassing first-quarter forecasts and raising full-year guidance, Intuitive Surgical (ISRG) stock exhibited strong bullish momentum. The positive market response can be explained by several factors:
• The company posted robust first-quarter earnings, achieving a 23% sales increase to $2.8 billion and profits of $821.5 million, exceeding market expectations.
• Sales growth was primarily fueled by a 16% rise in da Vinci surgical system procedures and a 39% increase in the Ion endoluminal system.
• Intuitive Surgical's optimistic outlook, anticipating sustained double-digit growth for da Vinci procedures in 2026 and an expansion of installed systems globally, likely influenced the bullish market trend. The company's solid financial performance and favorable earnings report further enhanced investor confidence in its future outlook.

04.01.2026 - ISRG Stock was down 5.1%

• Machina Capital S.A.S. and other significant institutional investors have notably increased their holdings in ISRG, signaling confidence in the company's future.
• Despite positive Q3 performance and strategic growth positioning, ISRG witnessed a bearish movement, potentially attributed to profit-taking or shifts in market sentiment.
• The upcoming earnings release from Zimmer Biomet Holdings (ZBH) might have impacted market dynamics, leading to a more cautious approach towards medical equipment stocks like ISRG.
• Market sentiments surrounding healthcare and medical technology sectors likely influenced ISRG's bearish movement, despite its favorable long-term growth prospects.

27.04.2026 - ISRG Stock was down 5.0%

• The stock experienced a 3.28% decline, hitting a 52-week low due to significant product recalls related to its da Vinci surgical systems, igniting worries about product reliability and regulatory oversight.
• Positive Q1 financial results and analyst upgrades were overshadowed by the lingering impact of the product recalls and valuation apprehensions, driving the bearish trend.
• An adjustment of the price target downward by Goldman Sachs, in conjunction with a maintained Buy rating, reflects the prevailing market challenges and evolving dynamics faced by the company, encompassing FDA actions and voluntary recalls that dampened the stock performance.
• The company's unveiling of updates to its da Vinci 5 robotic surgical system could serve as a potential trigger for future recovery, seeking to address investor uncertainties and bolster product dependability.

06.00.2026 - ISRG Stock was up 5.0%

• Noteworthy insider selling by Greenleaf Trust and Hennion & Walsh Asset Management Inc. did not deter overall market optimism towards ISRG today.
• Discussions around the utilization of Artificial Intelligence (AI) in the medical sector, including within companies like ISRG, likely influenced investor sentiment positively, reflecting interest in the company's growth prospects.
• ISRG's strong earnings report, surpassing revenue and EPS projections, is seen as a key factor reinforcing investor trust in the company's future performance.
• Variations in institutional investors' behavior, with some increasing stakes and others decreasing positions in ISRG, suggest diverse views on the company's long-term outlook. Nevertheless, the prevailing market sentiment remained favorable, supporting the bullish trend in ISRG.

27.04.2026 - ISRG Stock was down 5.1%

• AGoldman Sachs revised ISRG's price target from $621 to $558, while maintaining a Buy rating. This adjustment potentially impacted investor sentiment, contributing to the market decline.
• Despite being viewed as a stronger investment than Medtronic in the surgical robotics sector, recent actions by the FDA and voluntary recalls linked to its da Vinci Surgical System may have adversely affected ISRG's stock performance.
• The consolidation of ISRG shares post-earnings pullback, as investors assess valuation and hospital spending, likely intensified pressure on the stock price.
• The collective impact of adjusted price targets, regulatory issues, and post-earnings scrutiny are probable factors behind the bearish movement observed in ISRG's stock today.

14.00.2026 - ISRG Stock was down 5.5%

• Despite strong Q4 revenue and procedure growth, ISRG's stock saw a 6% decline in pre-market trading.
• Concerns regarding a slowdown in Ion endoluminal system placements, despite an increase in da Vinci system placements, appear to have fueled the bearish movement.
• Investor sentiment may have been influenced by the company's anticipation of a potential deceleration in da Vinci procedures growth for 2026.
• Watching for the stock's current undervaluation in comparison to estimated fair value, as well as expected advancements in AI-enabled surgery, could be crucial for potential future market movements.

13.02.2026 - ISRG Stock was down 4.7%

• The bearish movement in ISRG stock today could be attributed to:
• Mixed short-term share performance contrasting with significant long-term gains, raising concerns about potential valuation risks.
• Underperforming the general market, including the S&P 500, Dow, and Nasdaq, despite analysts anticipating strong earnings and revenue growth.
• The stock trading at a premium valuation compared to industry peers, potentially leading to profit-taking by investors.
• The acquisition of distributors in Southern Europe could be a positive long-term strategic move for ISRG, enhancing its direct presence in key markets and further solidifying its position in the region.
• Analysts' suggestions of undervaluation and expectations of revenue growth over the next 12 months may indicate a potential rebound in the stock price following today's decline.

11.04.2026 - ISRG Stock was down 5.2%

• ISRG stock plummeted by 5.77% due to a Class I FDA recall of certain staplers used with its da Vinci Surgical System, leading to serious injuries and one death. This news significantly impacted investor confidence in the company's technology and raised concerns about product safety.
• The additional selling pressure from major institutional investors like Koshinski Asset Management Inc. and Securian Asset Management Inc. further exacerbated the stock's decline, reflecting a lack of faith in ISRG's current valuation and potential future growth prospects.
• The broader sector-wide selling in medical technology stocks, including peers like Edwards Lifesciences and IDEXX Laboratories, suggests a macro or sentiment-driven market shift that contributed to ISRG's disproportionate fall. This market trend highlights the importance of monitoring industry dynamics and external factors that can influence stock performance.

11.04.2026 - ISRG Stock was down 4.6%

• The bearish movement in Intuitive Surgical's stock today could be attributed to the mixed activity of institutional investors in the fourth quarter of 2025, with one firm reducing its stake while another increased its position.
• The ongoing market debate surrounding the valuation and future growth trajectory of the company may have contributed to the market reassessment and subsequent bearish movement.
• Despite the fluctuations in investor sentiment, Intuitive Surgical's market dominance with its innovative da Vinci system and robust recurring revenue model remains a key strength for the company.
• The overall uncertainty and conflicting actions of institutional investors regarding ISRG stock could have led to today's bearish market movement.

04.05.2026 - ISRG Stock was up 5.3%

• Despite a recent 11% decline in ISRG shares, today's bullish movement could be attributed to several factors:
• The positive sentiment highlighting Intuitive Surgical as a strong contender in the healthcare sector may have attracted investors.
• The proposed sale of common stock could have been perceived as a routine financial decision rather than a cause for concern.
• Market participants may be viewing the recent pullback in ISRG shares as a buying opportunity, especially with the company's strong fundamentals and a Zacks Rank #2 (Buy) rating.
• The broader market concerns about ISRG's recent decline may have subsided, leading to renewed confidence in the stock's potential for growth.